Theratechnologies Inc.

250 articles with Theratechnologies Inc.

• 

  Clinical Catch-Up: Updates for Achilles, Logic Bio, Roche and More

  5/16/2022

  Achilles dosed the first patient in a Phase I/IIa advanced NSCLC trial, Logic Bio's pediatric methylmalonic acidemia study is back up and running and another look at Roche's TIGIT flop.

• Theratechnologies Initiates Basket Portion of TH1902 First-in-Human Study in Advanced Resistant Malignancies

  5/10/2022

  Theratechnologies Inc. a biopharmaceutical company focused on the development and commercialization of innovative therapies, today initiated enrollment of patients in the basket portion of the first-in-human study of TH1902, Theratechnologies’ investigational lead peptide drug conjugate (PDC) for the treatment of sortilin-expressing cancers.

• Theratechnologies Reports Financial Results for First Quarter Fiscal 2022 and Provides Business Update

  4/13/2022

  Theratechnologies Inc. today reported business highlights and financial results for the first quarter of fiscal year 2022 ended February 28, 2022 (Q1 2022).

• Theratechnologies to Announce Financial Results for Its First Quarter 2022

  3/31/2022

  Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced that it will report financial results for its first quarter of fiscal 2022 ended February 28, 2022 on Wednesday, April 13, 2022.

• Theratechnologies to Present Three Posters at AACR Including New In Vivo TH1902 Preclinical Data Demonstrating Tumor Growth Inhibition of Human Cancer Stem-Like Cells (CD133+) in Both Triple-Negative Breast and Ovarian Cancers

  3/8/2022

  Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that three poster abstracts have been accepted for presentation at the 2022 Annual Meeting of the American Association for Cancer Research (AACR) to be held April 8-13, 2022.

• Theratechnologies Reports Financial Results for Fiscal 2021 and Provides Business Update

  2/24/2022

  Theratechnologies Inc. today reported business highlights and financial results for its fourth quarter (Q4 2021) and full fiscal year (FY 2021) ended November 30, 2021.

• Theratechnologies Presents Results From Trogarzo® IV Push Administration Study at CROI 2022

  2/16/2022

  Theratechnologies Inc. today announced the presentation of positive results from the Phase 3 study evaluating an intravenous (IV) push method of administration of Trogarzo® for the treatment of human immunodeficiency virus type 1 (HIV-1).

• Theratechnologies Strengthens Global Commercial Capabilities by Launching Internal Field Force

  2/15/2022

  Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced the strengthening of its global commercial capabilities by launching an internal sales force.

• Theratechnologies to Announce Financial Results for Its Fourth Quarter and Full Fiscal Year 2021

  2/10/2022

  Theratechnologies Inc. announced today that it will report financial results for its fourth quarter of fiscal 2021 ended November 30, 2021 as well as for its full fiscal year 2021 on Thursday, February 24, 2022.

• Theratechnologies Submits Supplemental Biologics License Application to FDA Advancing Development of IV Push Trogarzo® for Patients Living With HIV

  12/6/2021

  Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce the submission of a supplemental biologics license application to the U.S. Food and Drug Administration for the Company’s intravenous push form of administration of Trogarzo®.

• Theratechnologies Named Recipient of the 2021 ADRIQ Innovation Award in the "Life Sciences" Category

  11/26/2021

  Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it was awarded of the 2021 Innovation Award in the “Life Sciences” category at the 31st ADRIQ Innovation Awards Gala held on November 25, 2021.

• Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021

  11/3/2021

  Theratechnologies Inc. today announced that Paul Levesque, President and Chief Executive Officer, will present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021 at 9:40 a.m. ET.

• Theratechnologies Announces Reimbursement Agreement in Italy for Trogarzo® for Eligible Patients With Multi-Drug Resistant HIV-1

  10/26/2021

  Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it has reached an agreement with the Italian Medicines Agency, AIFA, for the reimbursement of Trogarzo® for eligible people aged 18 and older living with multi-drug resistant HIV-1.

• Theratechnologies Announces Publication in Frontiers in Oncology Journal Highlighting SORT1+ Technology™ for Targeting SORT1-Mediated Vasculogenic Mimicry

  10/22/2021

  Theratechnologies Inc. is pleased to announce the publication of a peer-reviewed article demonstrating that the Company’s novel investigational peptide-drug conjugates (PDCs) TH1902 and TH1904

• Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2021 and Provides Business Update

  10/13/2021

  Theratechnologies Inc. today reported business highlights and financial results for its third quarter ended August 31, 2021 (Q3 Fiscal 2021).

• Theratechnologies to Present at the H.C. Wainwright 5th Annual Nash Investor Conference

  10/6/2021

  Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer, will participate at the H.C. Wainwright 5th Annual NASH Investor Conference.

• Theratechnologies to Announce Financial Results for Its Third Quarter Fiscal 2021

  9/29/2021

  Theratechnologies Inc. announced today that it will report financial results for its third quarter of fiscal 2021 ended August 31, 2021 on Wednesday, October 13, 2021.

• Theratechnologies Announces Positive Results for Trogarzo® IV Push Administration Study

  9/22/2021

  Theratechnologies Inc. is pleased to announce that a study evaluating an intravenous (IV) push form of administration of Trogarzo

• Theratechnologies to Present at the Cantor Fitzgerald Global Healthcare Conference on September 29, 2021

  9/16/2021

  Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer, will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference on September 29, 2021 at 10:00 a.m. ET.   

• Theratechnologies Announces Publication of TH1902 Preclinical Data in Peer-Reviewed Journal, Cancer Science

  8/13/2021

  Theratechnologies, Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), announced today the publication of data from its preclinical research of TH1902 for the treatment of sortilin-positive triple negative breast cancer (TNBC) in the peer-reviewed journal Cancer Science, confirming the in vivo efficacy and safety of TH1902 against TNBC through a SORT1 receptor-mediated mechanism.